

Jazz Pharmaceuticals (JAZZ)

\$146.74 (As of 01/29/20)

Price Target (6-12 Months): **\$124.00**

Long Term: 6-12 Months

Zacks Recommendation: Underperform

(Since: 01/28/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5)

5-Strong Sell

Zacks Style Scores:

VGM:B

Value: B

Growth: B

Momentum: D

Summary

Jazz's Xyrem generates the majority of the company's sales, and consequently any setback is likely to hamper Jazz's top line. Xyrem is set to face generic competition from 2023 along with other branded drugs under development. Moreover, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity. These supply challenges are expected to continue in 2019. Meanwhile, its newest drug Vyxeos faces strong competition in the acute myeloid leukemia market. However, management seems confident that Xyrem will continue to generate volume growth in future quarters. The company's new drug Sunosi complements its existing sleep disorder portfolio. Shares have outperformed the industry in the past year.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$154.24 - \$116.52
20 Day Average Volume (sh)	467,894
Market Cap	\$8.3 B
YTD Price Change	-1.7%
Beta	1.13
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Drugs
Zacks Industry Rank	Top 44% (112 out of 255)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	14.2%
Last Sales Surprise	2.9%
EPS F1 Est- 4 week change	-9.5%
Expected Report Date	02/25/2020
Earnings ESP	1.1%

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2020	545 E	591 E	607 E	634 E	2,371 E
2019	508 A	534 A	538 A	564 E	2,146 E
2018	445 A	500 A	469 A	476 A	1,891 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2020	\$3.85 E	\$4.44 E	\$4.59 E	\$4.84 E	\$17.46 E
2019	\$3.67 A	\$4.05 A	\$4.10 A	\$4.15 E	\$15.94 E
2018	\$2.98 A	\$3.49 A	\$3.58 A	\$3.64 A	\$13.70 A

*Quarterly figures may not add up to annual.

P/E TTM	9.5
P/E F1	8.4
PEG F1	0.9
P/S TTM	4.0


The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 01/29/2020. The reports text is as of 01/30/2020.

Overview

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of sleep and hematology/oncology. Key drugs include Xyrem for cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients, Erwinaze for acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity to E.coli-derived asparaginase, Defitelio for the treatment of patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT) and Vyxeos for the treatment of adults with two types of Acute Myeloid Leukemia (AML). Sunosi (solriamfetol) was approved for excessive sleepiness in narcolepsy & obstructive sleep apnea (OSA) in March 2019.

Jazz has bolstered its commercial portfolio and pipeline through acquisitions. These include addition of marketed drugs – Defitelio, Vyxeos and Erwinaze. Jazz also added solriamfetol, through one of these acquisitions.

In September 2018, the company sold all rights to pain drug, Prialt to TerSera. The company generates the majority of its revenues from Xyrem sales. The drug registered sales of \$1.41 billion, up 18% and almost 74% of total revenues, in 2018.



Reasons To Sell:

▼ **Regulation on Xyrem and Competition:** Xyrem is a controlled substance with a highly restricted distribution channel subject to a risk evaluation and mitigation strategy (REMS). In February 2015, the FDA approved Jazz's Xyrem REMS requiring distribution through a single pharmacy. Single pharmacy can put pressure on patient access as well as the overall healthcare delivery system. Moreover, the FDA plans to evaluate the Xyrem REMS on an ongoing basis and reserves the rights to make modifications if required, which can either lower entry barriers for companies looking to market generic versions of Xyrem or make it more expensive or difficult to market the drug.

The earlier-than-expected entry of Xyrem generics and any pipeline setback would weigh heavily on the stock.

Jazz had been involved in patent infringement lawsuits with generic drug makers for Xyrem. Several generic versions of Xyrem may hit the market in 2023. Launch of Xyrem's generic will unfavorably impact sales of the company's major drug. With nearly three-fourth of sales coming from Xyrem this will severely impact the company's top-line and weigh on share price. Moreover, the market for EDS in patients with narcolepsy is highly competitive, given the presence of Teva's Nuvigil and generic versions of Provigil, among others. Moreover, other companies are also developing treatments for similar indication including Avadel Pharmaceuticals' sodium oxybate formulation, FT-218.

▼ **Erwinaze Supply Constraints:** Jazz has been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity. This resulted in supply disruptions and hurt sales of Erwinaze in 2017, 2018 and 2019. The company anticipates the supply challenges to continue in 2020 as well. Moreover, in February 2019, Jazz received termination notice from Porton Biopharma related to license and supply of Erwinaze which is set to expire by 2020 end. Without renewing the agreement, Jazz will not be able to sell Erwinaze beginning 2021, except for certain Erwinaze inventory for 12 months post termination of the agreement.

▼ **Pipeline Setbacks:** Jazz has had its share of pipeline setbacks. Although solriamfetol achieved improvement in patients in a phase II study evaluating it in EDS and Parkinson's disease, the company discontinued further development in May 2019. In June 2019, Jazz's partner, ImmunoGen, discontinued development of its anti-body drug conjugate candidate, IMG779, for which Jazz possessed opt-in rights. In January 2016, the company terminated a phase II pivotal study on JZP-416 due to the occurrence of hypersensitivity-like reactions in patients suffering from ALL who are hypersensitive to pegylated E. coli-derived asparaginase. In addition to this, the company terminated a study evaluating Erwinaze in patients (18 to 39 years) suffering from ALL who are hypersensitive to E. coli-derived asparaginase due to its inability to enroll patients. Moreover, the company along with its partner Concert Pharmaceuticals decided not to move sleep disorder candidate, JZP-386, into the next stage of development following phase I study results.

Jazz decided to discontinue the late-stage development of Leukotac after the candidate failed in a clinical study as a treatment for patients who developed steroid-refractory acute graft-versus-host disease post allogeneic hematopoietic stem cell transplant. Discontinuation of development of important candidates could affect the company's growth prospects significantly.

Risks

- **Xyrem has Strong Commercial Potential:** Xyrem has immense commercial potential considering that it is the only FDA approved product for both cataplexy and EDS. Sales reps continue to educate healthcare providers on narcolepsy and the use of Xyrem with a focus on physicians with high narcolepsy potential and low Xyrem utilization. Volume trends for Xyrem improved in 2018 and the trend continues so far in 2019 supported by the company's disease awareness education efforts, which led to increased diagnosis rate of new narcolepsy patients. Management seems confident of generating volume growth in the rest of 2019.

The company is also striving to expand Xyrem's label. In October 2018, the FDA granted approval to the sNDA for Xyrem to include the pediatric patients with cataplexy or EDS. Jazz launched the drug for pediatric patients in March 2019, which is bringing in additional sales. Moreover, settlement of all patent litigation related to generic version removes an overhang. There is no generic competition expected till 2022 as of now.

- **Strong Sleep Disorder Portfolio:** Jazz's sleep disorder portfolio looks strong with the launch of Sunosi and several ongoing and planned development activities in the sleep therapeutic area.

In March 2019, Sunosi (solriamfetol), received approval in the United States for excessive sleepiness in narcolepsy & OSA and was launched in the United States in July 2019. The drug is under review in Europe for a similar indication with a decision expected by early 2020. In November 2019, the CHMP recommended the approval of the drug in Europe. According to Jazz, there is significant unmet need in narcolepsy and OSA with about 175-300K patients having an inadequate response to current wake-promoting therapies. The company plans to develop Sunosi as a potential treatment for EDS in other sleep or central nervous system disorders, including major depressive disorder.

Other than Sunosi, Jazz is also studying JZP-258 (a low sodium formulation of Xyrem) in phase III studies for EDS and cataplexy in narcolepsy patients. The filed an NDA in January 2020 based on phase III study data. JZP-258 is also being studied for Idiopathic hypersomnia, or IH in a phase III study.

Last Earnings Report

Jazz Pharmaceuticals Q3 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals delivered adjusted earnings of \$4.10 per share for the third quarter of 2019, which surpassed the Zacks Consensus Estimate of \$3.59. Earnings rose 15% from the year-ago figure driven by higher sales, which made up for higher operating expense.

Total revenues in the reported quarter rose 15% year over year to \$537.7 million and also beat the Zacks Consensus Estimate of \$523.0 million. This can be attributed to higher sales of Xyrem.

Quarter Ending **09/2019**

Report Date	Nov 05, 2019
Sales Surprise	2.87%
EPS Surprise	14.21%
Quarterly EPS	4.10
Annual EPS (TTM)	15.46

Quarter in Detail

Net product sales in the reported quarter increased 14.4% from the year-ago quarter to \$532.3 million. Royalties and contract revenues rose 28.9% to \$5.38 million in the quarter.

Sales of Xyrem rose 19% year over year to \$425.6 million. Sales were driven by a 6.5% rise in bottle volume growth. The average number of active Xyrem patients increased 5% in the quarter.

Volume trends for Xyrem improved supported by the company's disease awareness education efforts, which led to increased diagnosis rate of new narcolepsy patients.

Erwinaze/Erwinase revenues were \$34.0 million, down 17% year over year due to ongoing supply and manufacturing issues at its sole manufacturer, PDL. Defitelio sales rose 4% year over year to \$37.6 million in the quarter. However, Defitelio's sales declined sequentially. Defitelio product sales vary from quarter to quarter in both the United States and EU because Defitelio treats an ultra-rare acute condition — hepatic veno-occlusive disease.

Acute myeloid leukemia drug, Vyxeos generated sales of \$29.6 million, up 41% from the year-ago period, primarily due to the ongoing launch in EU. However, Vyxeos' sales declined sequentially.

Sunosi recorded sales of \$1 million in the quarter. Other product sales declined 53.3% to \$4.5 million.

Adjusted selling, general and administrative (SG&A) expenses rose 12.8% to \$158.4 million driven by higher expenses for business expansion and costs to support the launch of Sunosi in the United States.

Adjusted research and development (R&D) expenses increased 57.6% to \$73.4 million, primarily due to escalating expenses related to development of the company's pipeline and partnered programs.

2019 Guidance

The company raised its previously issued guidance for total revenues as well as earnings. However, the guidance includes only minimal net sales contribution from Sunosi in the United States.

It expects earnings in the range of \$15.50 - \$16.15 in 2019 versus the prior expectation of \$14.30-\$15.00 per share. Total revenues are expected to be higher in the range of \$2.10-\$2.18 billion compared with the previous range of \$2.07-\$2.15 billion. The 2019 sales and earnings ranges represent growth of 11-15% and 13-18%, respectively over 2018 levels.

Total product sales are predicted in the range of \$2.08-\$2.16 billion (previously \$2.055-\$2.125 billion) for 2019. The company raised the guidance for Xyrem sales to the range of \$1.60-\$1.64 billion from \$1.55-\$1.59 billion. Erwinaze/Erwinase sales forecast was maintained in the band of \$160-\$195 million.

Jazz raised the lower end of its guidance range for Defitelio from \$155-\$180 million to \$160-\$180 million. It lowered the higher end of its guidance range for Vyxeos from \$120-\$150 million to \$120-\$135 million.

While adjusted SG&A expenses are anticipated in the range of \$630 million to \$650 million (previously \$620 million to \$650 million), adjusted R&D expenses are expected to be in the band of \$245 million to \$265 million (previously \$235 million to \$265 million).

Recent News

Files NDA for JZP-258 – Jan 22

Jazz announced that it has submitted a NDA seeking approval for JZP-258 as a treatment for cataplexy and EDS associated with narcolepsy in patients seven years or younger. The company has redeemed a priority review voucher for the NDA submission.

Sunosi Gets Approval in Europe – Jan 20

Jazz announced that the European Commission approved Sunosi. The drug will be available in Europe as a treatment to improve wakefulness and reduce EDS in adults with narcolepsy (with or without cataplexy) or OSA, whose EDS has not been satisfactorily treated by primary OSA therapy.

Enrolls First Patient in Phase II/III Leukemia Study – Dec 30

Jazz announced that it has enrolled the first patient in the pivotal phase II/III study evaluating JZP-258 in pediatric and adult patients with ALL or LBL who are hypersensitive to E. coli-derived asparaginases.

This single-arm, open-label dose confirmation and confirmatory study is being conducted in collaboration with Children's Oncology Group.

Per the company, the study will assess the safety, tolerability and efficacy of JZP-458 in patients with ALL/LBL who have silent inactivation or an allergic reaction to E. coli-derived asparaginases having received no prior asparaginase Erwinia chrysanthemi.

The primary objective of the study is to determine the efficacy of JZP-458 measured by asparaginase activity.

Valuation

Jazz's shares are up 16.6% over the trailing 12-month period. Over the past year, the Zacks sub-industry is down 0.9 while the Zacks sector is up 2.3%.

The S&P 500 Index is up 20.1% in the past year.

The stock is currently trading at 4.1X trailing 12-month sales per share, which compares to 3.32X for the Zacks sub-industry, 3.12X for the Zacks sector and 3.54X for the S&P 500 index.

Over the past five years, the stock has traded as high as 10.13X and as low as 3.31X, with a 5-year median of 5.71X. Our Underperform recommendation indicates that the stock will perform worse than the market. Our \$124.00 price target reflects 3.46X trailing 12-month sales per share.

The table below shows summary valuation data for JAZZ

Valuation Multiples - JAZZ					
		Stock	Sub-Industry	Sector	S&P 500
P/S TTM	Current	4.1	3.32	3.12	3.54
	5-Year High	10.13	4.15	4.14	3.65
	5-Year Low	3.31	2	2.74	2.56
	5-Year Median	5.71	2.62	3.26	3.16
P/B TTM	Current	2.72	1.59	4.52	4.48
	5-Year High	8.93	12.54	5.02	4.55
	5-Year Low	2.25	0.96	3.48	2.9
	5-Year Median	3.96	2.52	4.28	3.62

As of 01/29/2020

Industry Analysis Zacks Industry Rank: Top 44% (112 out of 255)



Top Peers

Alexion Pharmaceuticals, Inc. (ALXN)	Outperform
Alkermes plc (ALKS)	Neutral
Avadel Pharmaceuticals PLC. (AVDL)	Neutral
BioMarin Pharmaceutical Inc. (BMRN)	Neutral
Endo International plc (ENDP)	Neutral
Horizon Therapeutics Public Limited Company (HZNP)	Neutral
Incyte Corporation (INCY)	Neutral
Ionis Pharmaceuticals, Inc. (IONS)	Neutral

Industry Comparison Industry: Medical - Drugs				Industry Peers		
	JAZZ Underperform	X Industry	S&P 500	ALKS Neutral	ALXN Outperform	BMRN Neutral
VGM Score	B	-	-	C	A	B
Market Cap	8.30 B	117.77 M	23.91 B	2.81 B	23.66 B	15.51 B
# of Analysts	11	2	13	8	14	10
Dividend Yield	0.00%	0.00%	1.77%	0.00%	0.00%	0.00%
Value Score	B	-	-	C	B	D
Cash/Price	0.13	0.28	0.04	0.21	0.10	0.05
EV/EBITDA	10.33	-2.12	14.07	-316.79	32.21	-5,190.99
PEG Ratio	0.92	1.16	2.00	1.58	0.64	NA
Price/Book (P/B)	2.72	3.08	3.27	2.63	2.28	5.05
Price/Cash Flow (P/CF)	8.76	10.56	13.48	28.78	11.83	403.41
P/E (F1)	8.33	15.06	18.76	32.91	9.42	48.59
Price/Sales (P/S)	4.04	5.75	2.61	2.61	5.00	9.68
Earnings Yield	11.90%	-14.64%	5.32%	3.03%	10.62%	2.06%
Debt/Equity	0.56	0.03	0.72	0.26	0.25	0.27
Cash Flow (\$/share)	16.75	-0.59	6.88	0.62	9.04	0.21
Growth Score	B	-	-	B	A	A
Hist. EPS Growth (3-5 yrs)	14.93%	8.54%	10.68%	NA	17.67%	NA
Proj. EPS Growth (F1/F0)	9.50%	17.26%	7.73%	2.34%	8.71%	98.14%
Curr. Cash Flow Growth	29.40%	13.56%	12.29%	126.78%	20.32%	-246.03%
Hist. Cash Flow Growth (3-5 yrs)	18.61%	8.38%	8.78%	-9.18%	26.87%	21.12%
Current Ratio	3.89	3.65	1.23	2.69	3.98	3.77
Debt/Capital	36.08%	7.98%	43.16%	20.46%	19.89%	21.53%
Net Margin	29.61%	-110.57%	11.59%	-18.71%	31.05%	-2.65%
Return on Equity	27.99%	-67.23%	17.38%	-6.08%	21.21%	-1.35%
Sales/Assets	0.38	0.29	0.54	0.61	0.33	0.36
Proj. Sales Growth (F1/F0)	10.52%	9.10%	4.05%	-8.38%	13.94%	15.20%
Momentum Score	D	-	-	F	A	C
Daily Price Chg	0.51%	0.00%	-0.21%	0.23%	-0.03%	0.55%
1 Week Price Chg	-3.52%	-3.24%	-1.09%	-8.42%	-7.06%	-2.40%
4 Week Price Chg	-1.70%	-0.10%	-0.01%	-12.70%	-1.12%	2.14%
12 Week Price Chg	15.30%	1.38%	4.14%	-9.59%	0.29%	15.39%
52 Week Price Chg	16.93%	-17.13%	17.24%	-45.70%	-11.85%	-10.94%
20 Day Average Volume	467,894	188,729	1,824,613	1,373,951	1,670,672	1,294,987
(F1) EPS Est 1 week change	-9.54%	0.00%	0.00%	-19.05%	0.45%	0.00%
(F1) EPS Est 4 week change	-9.54%	0.00%	0.00%	-19.05%	1.81%	0.00%
(F1) EPS Est 12 week change	-9.54%	2.80%	-0.11%	48.98%	2.65%	0.00%
(Q1) EPS Est Mthly Chg	NA%	0.00%	0.00%	0.00%	5.00%	0.00%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	D
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.